Search Results

2024 BioCapital Digital (2)

2024 BioForest Digital (11)

2024 BioForest Standard (1)

2024 BioMidwest Digital (3)

2024 BioMidwest Standard (2)

2024 Bio NC Digital (3)

2024 Bio NC Standard (1)

2024 Biotech Bay Standard (14)

2024 Biotech Beach Digital (4)

2024 Biotech Beach Standard (6)

2024 Genetown Digital (2)

2024 Genetown Standard (8)

2024 Lone Star Bio Digital (2)

2024 Pharm Country Digital (4)

2024 Pharm Country Standard (4)

2025 BioForest Digital (3)

2025 Lone Star Bio Digital (2)

2026 BioCapital Elite (1)

2026 BioCapital Standard (1)

2026 BioMidwest Elite (2)

2026 Bio NC Standard (1)

2026 Biotech Bay Elite (1)

2026 Biotech Beach Elite (2)

2026 Genetown Elite (3)

2026 Genetown Standard (1)

2026 Pharm Country Elite (1)

2026 Pharm Country Premier (1)

2026 Pharm Country Standard (2)

Academia (2880)

Accelerated approval (6)

Adcomms (28)

Allergies (89)

Alliances (48525)

ALS (97)

Alzheimer's disease (1446)

Antibody-drug conjugate (ADC) (145)

Approvals (16064)

Artificial intelligence (276)

Autoimmune disease (27)

Automation (14)

Bankruptcy (352)

Best Places to Work (12199)

BIOSECURE Act (22)

Biosimilars (116)

Biotechnology (126)

Bladder cancer (82)

Brain cancer (31)

Breast cancer (293)

Cancer (2360)

Cardiovascular disease (200)

Career advice (2835)

Career pathing (34)

CAR-T (162)

Cell therapy (453)

Cervical cancer (20)

Clinical research (64177)

Collaboration (871)

Compensation (472)

Complete response letters (29)

COVID-19 (2821)

CRISPR (46)

C-suite (258)

Cystic fibrosis (105)

Data (2229)

Decentralized trials (2)

Denatured (33)

Depression (52)

Diabetes (289)

Diagnostics (6689)

Digital health (19)

Diversity (9)

Diversity, equity & inclusion (45)

Drug discovery (130)

Drug pricing (124)

Drug shortages (32)

Duchenne muscular dystrophy (99)

Earnings (80899)

Editorial (43)

Employer branding (24)

Employer resources (160)

Events (108820)

Executive appointments (758)

FDA (17364)

Featured Employer (45)

Fibrodysplasia Ossificans Progressiva (1)

Friedreich's ataxia (4)

Frontotemporal dementia (8)

Funding (793)

Gene editing (116)

Generative AI (24)

Gene therapy (339)

GLP-1 (829)

Government (4894)

Grass and pollen (6)

Guidances (54)

Healthcare (20167)

Huntington's disease (24)

IgA nephropathy (31)

Immunology and inflammation (141)

Indications (30)

Infectious disease (2978)

Inflammatory bowel disease (147)

Inflation Reduction Act (11)

Influenza (54)

Intellectual property (99)

Interviews (647)

IPO (17020)

IRA (50)

Job creations (3598)

Job search strategy (2317)

Kidney cancer (11)

Labor market (40)

Layoffs (520)

Leadership (23)

Legal (8516)

Liver cancer (78)

Lung cancer (338)

Lymphoma (156)

Machine learning (7)

Management (63)

Manufacturing (333)

MASH (73)

Medical device (13864)

Medtech (13869)

Mergers & acquisitions (19108)

Metabolic disorders (766)

Multiple sclerosis (83)

NASH (23)

Neurodegenerative disease (111)

Neuropsychiatric disorders (34)

Neuroscience (2029)

NextGen: Class of 2025 (7124)

Non-profit (4903)

Northern California (2626)

Now hiring (38)

Obesity (415)

Opinion (271)

Ovarian cancer (77)

Pain (89)

Pancreatic cancer (83)

Parkinson's disease (157)

Partnered (21)

Patents (239)

Patient recruitment (107)

Peanut (49)

People (58529)

Pharmaceutical (54)

Pharmacy benefit managers (20)

Phase I (19810)

Phase II (28325)

Phase III (21543)

Pipeline (1219)

Policy (168)

Postmarket research (2402)

Preclinical (8318)

Press Release (69)

Prostate cancer (111)

Psychedelics (38)

Radiopharmaceuticals (262)

Rare diseases (419)

Real estate (6025)

Recruiting (73)

Regulatory (22938)

Reports (44)

Research institute (2536)

Resumes & cover letters (555)

Rett syndrome (5)

RNA editing (4)

RSV (50)

Schizophrenia (78)

Series A (141)

Series B (90)

Service/supplier (19)

Sickle cell disease (57)

Southern California (2266)

Special edition (18)

Spinal muscular atrophy (158)